Sensei Biotherapeutics–SEVERAL: investment, 202010 financing round Series A $28.5m co-led by Cambrian Biopharma + H&S Ventures |
2020-10-07 |
A2 Biotherapeutics–Nextech: investment, 202010 financing round Series B totalling $71.5m incl existing investor Nextech Invest |
2020-10-06 |
A2 Biotherapeutics–SEVERAL: investment, 202010 financing round Series B $71.5m |
2020-10-06 |
Novartis–Merck (DE): Nanobodies, 202010– license €50m upfront + €400m milestones to M6495 anti-ADAMTS5 Nanobody for osteoarthritis |
2020-10-06 |
Heartbeat Medical–btov Partners: investment, 202010 financing round Series A totalling €5m incl new + co-lead investor btov Partners |
2020-10-05 |
Heartbeat Medical–High-Tech Gründerfonds: investment, 202010 financing round Series A totalling €5m incl existing + co-investor HTGF |
2020-10-05 |
Heartbeat Medical–Holtzbrinck: investment, 202010 financing round Series A totalling €5m incl existing + co-lead investor HV Holtzbrinck Ventures |
2020-10-05 |
Heartbeat Medical–SEVERAL: investment, 202010 financing round Series A €5m co-led by btov Partners + HV Holtzbrinck Ventures + incl HTGF |
2020-10-05 |
BIA Separations–Sartorius: investment, 202010– acquisition €240m in cash + €120m in SSB shares BIA to be merged into SSB ANNOUNCED |
2020-10-02 |
AexeRNA Therapeutics–Linden Lake Venture Capital: investment, 202010 co-founding investor Linden Lake Venture Capital |
2020-10-01 |
ECBF–Corbion: investment, 201911–202010 first closing totalling €82m incl co-investor Corbion NV |
2020-10-01 |
ECBF–Hettich Beteiligungen: investment, 201911–202010 first closing totalling €82m incl co-investor Dr Hettich Beteiligungen GmbH |
2020-10-01 |
ECBF–PreZero International: investment, 201911–202010 first closing totalling €82m incl co-investor PreZero International GmbH |
2020-10-01 |
PeelPioneers–ECBF: investment, 202010 investment by ECBF in PeelPioneers BV |
2020-10-01 |
Prolupin–ECBF: investment, 202010 investment by ECBF in Prolupin GmbH |
2020-10-01 |
Sophia Genetics–ACE & Company: investment, 202010 financing round Series F totalling $110m incl new + co-investor ACE & Co |
2020-10-01 |
Sophia Genetics–Alychlo: investment, 202010 financing round Series F totalling $110m incl existing + co-investor Alychlo |
2020-10-01 |
Sophia Genetics–aMoon: investment, 202010 financing round Series F totalling $110m incl co-lead investor aMoon |
2020-10-01 |
Sophia Genetics–Credit Suisse: investment, 202010 financing round Series F totalling $110m incl co-investor Credit Suisse |
2020-10-01 |
Sophia Genetics–Endeavour Vision: investment, 202010 financing round Series F totalling $110m incl existing + co-investor Endeavour Vision |
2020-10-01 |
Sophia Genetics–Eurazeo: investment, 202010 financing round Series F totalling $110m incl existing + co-investor Eurazeo Growth |
2020-10-01 |
Sophia Genetics–Famille C Invest: investment, 202010 financing round Series F totalling $110m incl new + co-investor Famille C Invest |
2020-10-01 |
Sophia Genetics–Generation Investment Management: investment, 202010 financing round Series F totalling $110m incl existing + co-investor GIM |
2020-10-01 |
Sophia Genetics–Hitachi: investment, 202010 financing round Series F totalling $110m incl co-lead investor Hitachi Ventures |
2020-10-01 |
Sophia Genetics–Pictet: investment, 202010 financing round Series F totalling $110m incl co-investor Pictet Group |
2020-10-01 |
Sophia Genetics–SEVERAL: investment, 202010 financing round Series F $110m led by aMoon + Hitachi Ventures |
2020-10-01 |
Sophia Genetics–Swisscom: investment, 202010 financing round Series F totalling $110m incl existing + co-investor Swisscom Ventures |
2020-10-01 |
Wise (IT)–SEVERAL: investment, 202010 financing round Series C €15m led by CDP Venture Capital SGR |
2020-10-01 |
Integrated Proteomics Applications–Bruker: investment, 202009 acquisition €na of assets by Bruker |
2020-09-30 |
Vedere Bio–Novartis: investment, 202009 acquisition $150m upfront + $130m milestones with some assets spun out before into Vedere BIo II |
2020-09-30 |
Dewpoint Therapeutics–ARCH Venture: investment, 202009 financing round Series B totalling $77m incl lead investor ARCH Venture Partners |
2020-09-29 |
Dewpoint Therapeutics–Bayer: investment, 202009 financing round Series B totalling $77m incl existing + co-investor Leaps by Bayer |
2020-09-29 |
Dewpoint Therapeutics–Bellco Capital: investment, 202009 financing round Series B totalling $77m incl new + co-investor Bellco Capital |
2020-09-29 |
Dewpoint Therapeutics–EcoR1 Capital: investment, 202009 financing round Series B totalling $77m incl existing + co-investor EcoR1 Capital |
2020-09-29 |
Dewpoint Therapeutics–Innovation Endeavors: investment, 202009 financing round Series B totalling $77m incl existing + co-investor IE |
2020-09-29 |
Dewpoint Therapeutics–Maverick Ventures: investment, 202009 financing round Series B totalling $77m incl new + co-investor Maverick Ventures |
2020-09-29 |
Dewpoint Therapeutics–Polaris Partners: investment, 202009 financing round Series B totalling $77m incl existing + co-investor Polaris Partners |
2020-09-29 |
Dewpoint Therapeutics–Samsara BioCapital: investment, 202009 financing round Series B totalling $77m incl existing + co-investor Samsara BioCapital |
2020-09-29 |
Dewpoint Therapeutics–SEVERAL: investment, 202009 financing round Series B $77m led by ARCH Venture Partners |
2020-09-29 |
Kurma–SEVERAL: investment, 202009 first closing €50m of Kurma Diagnostics 2 Fund (KDx2) |
2020-09-29 |
Basel (govt)–Optimum Strategic Communications: public relations, 202009 service existent by Optimum for BaseLaunch |
2020-09-28 |
Prolytic–Kymos: investment, 202009 strategic merger of Polytic GmbH + Kymos SL |
2020-09-28 |
XtalPi–SEVERAL: investment, 202009 financing round Series C $318.8m co-led by SoftBank Vision Fund 2 + PICC Capital + Morningside |
2020-09-28 |
XtalPi–Swiss Investment Group: investment, 202009 financing round Series C totalling $318.8m incl existing + co-investor SIG |
2020-09-28 |
Galecto–HBM: investment, 202009 financing round totalling $64m incl existing + co-investor HBM Healthcare Investments |
2020-09-25 |
Galecto–SEVERAL: investment, 202009 financing round $64m led by Soleus + co-lead by Eir Ventures |
2020-09-25 |
Mosa Meat–Bell Food: investment, 202009 financing round Series B 1st closing totalling $55m incl existing + co-investor Bell Food Group |
2020-09-25 |
Mosa Meat–Blue Horizon Ventures: investment, 202009 financing round Series B 1st closing totalling $55m incl new + lead investor Blue Horizon Ventures |
2020-09-25 |
Mosa Meat–Merck (DE): investment, 202009 financing round Series B 1st closing totalling $55m incl existing + co-investor M Ventures |
2020-09-25 |
Mosa Meat–SEVERAL: investment, 202009 financing round Series B 1st closing $55m led by Blue Horizon Ventures |
2020-09-25 |
Monte Rosa Therapeutics–1AB Media: public relations, 202009 service existent by 1AB Media |
2020-09-24 |
Monte Rosa Therapeutics–Aisling Capital: investment, 202009 financing round Series B totalling $96m incl new + lead investor Aisling Capital |
2020-09-24 |
Monte Rosa Therapeutics–Alphabet: investment, 202009 financing round Series B totalling $96m incl new + co-investor GV |
2020-09-24 |
Monte Rosa Therapeutics–Amzak Health: investment, 202009 financing round Series B totalling $96m incl new + co-investor Amzak Health |
2020-09-24 |
Monte Rosa Therapeutics–Cambridge Asset Management: investment, 202009 financing round Series B totalling $96m incl new + co-investor CAM |
2020-09-24 |
Monte Rosa Therapeutics–Casdin Capital: investment, 202009 financing round Series B totalling $96m incl new + co-investor Casdin Capital |
2020-09-24 |
Monte Rosa Therapeutics–Cormorant Asset Management: investment, 202009 financing round Series B totalling $96m incl new + co-investor Cormorant |
2020-09-24 |
Monte Rosa Therapeutics–HBM: investment, 202009 financing round Series B totalling $96m incl new + co-investor HBM Healthcare Investments |
2020-09-24 |
Monte Rosa Therapeutics–New Enterprise Associates: investment, 202009 financing round Series B totalling $96m incl existing + co-investor NEA |
2020-09-24 |
Monte Rosa Therapeutics–SEVERAL: investment, 202009 financing round Series B $96m led by AIsling Capital |
2020-09-24 |
Monte Rosa Therapeutics–Sixty Degree Capital: investment, 202009 financing round Series B totalling $96m incl new + co-investor Sixty Degree Capital |
2020-09-24 |
Monte Rosa Therapeutics–Versant Ventures: investment, 202009 financing round Series B totalling $96m incl existing + co-investor Versant Ventures |
2020-09-24 |
AM-Pharma–Bellevue: investment, 202009 existent portfolio company of BB Pureos Bioventures LP |
2020-09-23 |
Bellevue–SEVERAL: investment, 202009 Closing $170m of BB Pureos Bioventures LP fund |
2020-09-23 |
Libra Therapeutics–Boehringer: investment, 202009 financing round Series A totalling $29m incl co-lead investor BIVF |
2020-09-23 |
Libra Therapeutics–SEVERAL: investment, 202009 financing round Series A $29m co-led by BIVF + Epidarex Capital + Santé |
2020-09-23 |
ERS Genomics–Zyme Communications: public relations, 202009 service existent by Zyme |
2020-09-22 |
Jennewein Biotechnologie–Chr. Hansen: investment, 202009– acquisition €310m on debt-free basis ANNOUNCED |
2020-09-22 |
Salvia BioElectronics–SEVERAL: investment, 202009 financing round Series A €21m co-led by Panakès Partners + Inkef Capital + SHS |
2020-09-22 |
Salvia BioElectronics–SHS Capital: investment, 202009 financing round Series A totalling €21m incl new + co-lead investor SHS |
2020-09-22 |
GeneWerk–Ampersand: investment, 202009 majority investment in GeneWerk GmbH by Ampersand Capital Partners |
2020-09-21 |
Immune Regulation–Metellus: investment, 202009– financing round Series B totalling £40.6m incl co-investor Metellus AG |
2020-09-21 |
Immune Regulation–SEVERAL: investment, 202009– financing round Series B £40.6m in two tranches + incl £6m advance subscription funds |
2020-09-21 |
Inflazome–Byrne Wallace: legal services, 202009 supply service Byrne Wallace is legal advisor with regard to acquisition of Inflazome by Roche |
2020-09-21 |
Inflazome–Goodwin Procter: legal services, 202009 supply service Goodwin Procter is legal advisor with regard to acquisition of Inflazome by Roche |
2020-09-21 |
Inflazome–Lazard: financial services, 202009 supply service Lazard financial advisor with regard to acquisition of Inflazome by Roche |
2020-09-21 |
Inflazome–Roche: investment, 202009 acquisition of Inflazome by Roche for €380m upfront + milestones |
2020-09-21 |
Infarm–SEVERAL: investment, 202009 financing round Series C first closing $170m led by LGT Lightstone |
2020-09-17 |
Lava Therapeutics–Bellevue: investment, 202009 financing round Series C totalling $83m incl new + co-investor BB Pureos Bioventures |
2020-09-17 |
Lava Therapeutics–SEVERAL: investment, 202009 financing round Series C $83m co-led by Novo Ventures + Sanofi Ventures |
2020-09-17 |
Novartis–BioNTech: investment, 202009– acquisition of Novartis GMP Biologics Manufacturing Site in Marburg by BioNTech |
2020-09-17 |
Dinaqor–KWM Communications: public relations, 202009 service existent by KWM Communications |
2020-09-16 |
Maetrics–Regulatory and Quality Solutions: investment, 202009 acquisition of Maetrics by R&Q |
2020-09-16 |
Moderna–Cabinet Privé de Conseils: public relations, 202009 service existent CPC is Swiss media contact |
2020-09-16 |
ImCheck Therapeutics–Bellevue: investment, 202009 financing round Series B extension €6m from BB Pureos Bioventures bringing total Series B to €54m |
2020-09-15 |
Evotec–BIOASTER: antiinfectives, 202009– collab research to establish tech + innovation hub in Lyon work started in early 2020 |
2020-09-14 |
Boehringer–Click Therapeutics: digital therapeutics, 202009– collab ufpront+milestones >$500m + royalties ww dev+marketing CT-155 for schizophrenia |
2020-09-11 |
Canopy Biosciences–Bruker: investment, 202009 acquisition €na of Canopy Biosciences LLC by Bruker Corp |
2020-09-11 |
Sumitomo–Gain Therapeutics: small-molecule drugs, 202009– collab strategic RnD targeting allosteric sites in lysosomal enzymes using SEE-Tx |
2020-09-10 |
Bayer–Recursion Pharmaceuticals: AI-based drug discovery, 202009– strategic collab to discover + develop small-molecules for fibrotic diseases |
2020-09-09 |
Oncomfort–SEVERAL: investment, 202009 financing round Series A €10m co-led by Debiopharm + Crédit Mutuel Innovation |
2020-09-09 |
Recursion Pharmaceuticals–Bayer: investment, 202009 financing round Series D totalling $239m incl $50m from new + lead investor Leaps by Bayer |
2020-09-09 |
Recursion Pharmaceuticals–SEVERAL: investment, 202009 financing round Series D $239m led by Leaps by Bayer |
2020-09-09 |
United States (govt)–Valneva: Japanese encephalitis vaccine, 202009–202308 supply $61m + option for up to $105m of Ixiaro to US DoD |
2020-09-09 |
Imcyse–MC Services: public relations, 202009 service existent by MC Services |
2020-09-07 |
Boehringer–BiomX: biomarker discovery, 202009– collab discovery of microbiome-based biomarkers for IBD using XMarker platform |
2020-09-02 |
Evotec–Univ Oxford: biobanking, 202009– collab €na granting Evotec access to QUOD biobank for multi-omics analyses for drug discovery |
2020-09-02 |
BioVersys–SEVERAL: investment, 202009 financing round Series B CHF19m |
2020-09-01 |
Helmholtz–Bruker: NMR spectrometer, 202009c supply 1.2 GHz NMR spectrometer with 28 Tesla to FZ Jülich |
2020-09-01 |
Lobsor–Stada: investment, 202009 acquisition of Lobsor Pharmaceuticals AB by Stada/Britannia |
2020-09-01 |